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Abstract
The mortality rate of patients with schizophrenia is high, and life expectancy is shorter by 10 to 20  years. Metabolic 
abnormalities including type 2 diabetes mellitus (T2DM) are among the main reasons. The prevalence of T2DM in patients 
with schizophrenia may be epidemiologically frequent because antipsychotics induce weight gain as a side effect and the 
cognitive dysfunction of patients with schizophrenia relates to a disordered lifestyle, poor diet, and low socioeconomic 
status. Apart from these common risk factors and risk factors unique to schizophrenia, accumulating evidence suggests the 
existence of common susceptibility genes between schizophrenia and T2DM. Functional proteins translated from common 
genetic susceptibility genes are known to regulate neuronal development in the brain and insulin in the pancreas through 
several common cascades. In this review, we discuss common susceptibility genes, functional cascades, and the relationship 
between schizophrenia and T2DM. Many genetic and epidemiological studies have reliably associated the comorbidity of 
schizophrenia and T2DM, and it is probably safe to think that common cascades and mechanisms suspected from common 
genes’ functions are related to the onset of both schizophrenia and T2DM. On the other hand, even when genetic analyses 
are performed on a relatively large number of comorbid patients, the results are sometimes inconsistent, and susceptibility 
genes may carry only a low or moderate risk. We anticipate future directions in this field.
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Introduction
Schizophrenia is found in all cultures and appears to affect 0.5% 
to 1.5% of people during their lifetime (Pedersen et  al., 2014). 
Due to its early age of onset and subsequent tendency to per-
sist chronically, it produces great suffering for patients and their 
family members (Weinberger and Harrison, 2011). The mortality 
rate of patients with schizophrenia is twice as high as that of 
the general population, and their life expectancy is 10–20 years 
shorter (Crump et al., 2013; Lawrence et al., 2013). Although sui-
cide and other unnatural causes account for more than 10% 
of the excess mortality, a substantial proportion of this excess 
mortality is due to the increased comorbidity of various med-
ical illnesses in patients with schizophrenia (Crump et al., 2013; 
Lawrence et al., 2013; Olfson et al., 2015). Patients with schizo-
phrenia have an increased risk for development of type 2 dia-
betes mellitus (T2DM). The prevalence of T2DM in patients with 
schizophrenia is approximately 6% to 21%, 2 to 3 times higher 
than in the general population (Mitchell et  al., 2013; Stubbs 
et al., 2015). T2DM manifests as persistent hyperglycemia due 
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to pancreatic beta-cell dysfunction, which leads to long-term 
complications. T2DM is a major risk factor for cardiovascular 
disease, and cardiovascular disease is the main cause of a sub-
stantial proportion of excess deaths of patients with schizo-
phrenia (Murray et al., 2012; Lawrence et al., 2013; Olfson et al., 
2015).
The mechanisms of the increasing prevalence of T2DM in pa-
tients with schizophrenia are multifactorial. T2DM and schizo-
phrenia are caused by shared etiological factors (Ward and 
Druss, 2015). Traditional risk factors include a sedentary life-
style and poor diet (Ward and Druss, 2015). Risk factors unique 
to schizophrenia include low socioeconomic status, cognitive 
dysfunction, and iatrogenic risk during treatment with anti-
psychotics (Ward and Druss, 2015). Some evidence suggests that 
a longer duration of schizophrenia increases the risk for dia-
betes (Philippe et al., 2005; Nuevo et al., 2011). Patients who have 
had schizophrenia for more than 25 years have nearly twice the 
risk for diabetes as those with less than 25 years since the first 
admission to hospital (Philippe et al., 2005). It has been found 
that impaired hormonal regulation of appetite, in terms of low 
leptin and high insulin levels, often occurs in early psychosis be-
fore antipsychotic treatment (Misiak et al., 2019; Lis et al., 2020a, 
2020b). Hence, schizophrenia itself is a risk for increased onset 
of diabetes. Apart from these traditional risk factors and risk fac-
tors unique to schizophrenia, recent studies show an elevated 
risk of T2DM among drug-naïve or first-episode patients with 
schizophrenia and their relatives (Perry et  al., 2016; Pillinger 
et al., 2017; Rajkumar et al., 2017). A recent systematic review and 
meta-analysis of glucose homeostasis in unaffected first-degree 
relatives of schizophrenia patients suggested impaired glucose 
tolerance in this population as well (Misiak et al., 2020). Thus, 
previous evidence has strongly suggested that schizophrenia 
and T2DM are caused by multiple genetic variants (Gough and 
O’Donovan, 2005). Multiple twin and family studies and herit-
ability of intermediate phenotypes provide convincing evidence 
for an important role of the genetic etiologies, respectively (Das 
and Elbein, 2006; Demjaha et al., 2012). The risk of T2DM in pa-
tients with psychoses such as schizophrenia is elevated two- to 
fourfold in association with a positive family history of diabetes 
(Foley et al., 2014; Chung and Miller, 2020). Further, one-half of 
patients with schizophrenia are reported to have a family history 
of T2DM compared with 4.6% of healthy adult controls (Bushe 
and Holt, 2004). Interestingly, the polygenic risk score related to 
the onset of schizophrenia is also associated with insulin re-
sistance in first-episode and antipsychotic-naive patients with 
schizophrenia (Tomasik et  al., 2019). Thus, schizophrenia and 
T2DM may influence each other and share susceptibility gene 
variants.
Accumulating evidence indicates that potential environ-
mental risk factors affecting both the premorbid phase and 
after the onset of schizophrenia include exposure to stress in 
early life, poor dietary habits, and a sedentary life style, as noted 
above. Stress leads to the alteration of several biological mech-
anisms that has been termed “allostasis” (Misiak et  al., 2014). 
These processes enable adaptation to novel situations. However, 
their prolonged and cumulative activation exerts systemic and 
detrimental effects called the allostatic load (AL) (Juster et al., 
2016; Misiak, 2019). The AL concept can be a useful framework 
for apprehending biological dysregulations related to chronic 
stress. Biological alterations associated with AL (AL mediators) 
in schizophrenia include a subclinical inflammatory state, en-
hanced oxidative stress levels, decreased level of neurotrophins, 
and impaired hypothalamic-pituitary-adrenal (HPA) axis re-
sponse (Misiak et al., 2014). There are also markers that enable 
the measurement of AL (AL index). A higher AL index has been 
associated with a higher severity of positive and depressive 
symptoms, working memory impairments, lower general func-
tioning, and health outcomes, including all-cause mortality 
(Misiak, 2019; Piotrowski et al., 2019).
In this review, we describe the comorbidity of schizophrenia 
and T2DM in genetic and functional pathways. First, we de-
scribe susceptibility genes common to schizophrenia and T2DM 
(Table 1). Second, we discuss molecular mechanisms that 
might explain a common functional cascade in schizophrenia 
and T2DM. Third, we describe common mechanisms in schizo-
phrenia and T2DM, such as inflammation, oxidative stress, and 
HPA axis dysfunction.
Common Susceptibility Genes in Schizophrenia and 
T2DM 
Previous family-based genome-wide linkage studies show that 
schizophrenia and T2DM have a number of overlapping risk loci, 
including chromosomes 1p13, 1p36, 1q21–24, 1q25, 2q14, 2q33, 
2q36, 3p22, 3q29, 4q25, 5q13, 6p21, 6q25, 7p15, 7p21, 7q21, 7q31, 
and 9p24 (Lin and Shuldiner, 2010). These loci include gene-rich 
regions that will harbor multiple common candidate genes for 
susceptibility to schizophrenia and T2DM. Although many of 
these loci cover large distances in genomic DNA, chromosome 
1q was reported to have a linkage to T2DM by several previous 
studies (Das and Elbein, 2007; Tziastoudi et  al., 2019). This lo-
cation has also been implicated as a schizophrenia suscepti-
bility locus (Brzustowicz et al., 2000). Therefore, these findings 
have suggested that chromosome 1q may be remarkably rich in 
linkage findings for co-occurrence of schizophrenia and T2DM. 
Within this region of linkage, susceptibility genes for T2DM 
such as endogenous retrovirus group K member 18 (Herv K-18) 
and Rho guanine-nucleotide exchange factor 11 (ARHGEF11) 
(Böttcher et  al., 2008) have been found to be associated with 
schizophrenia among sampled populations (Dickerson et  al., 
2008; Mizuki et al., 2014).
The most straightforward method to identify the genetic 
risk for comorbidity of schizophrenia and T2DM is searching 
for overlapped candidate genes or regions of these 2 individual 
diseases (Lin and Shuldiner, 2010). Common candidate genes 
shared by association studies focused on each individual 
disease are glutathione S-transferase mu 1 (GSTM1), gluta-
thione S-transferase theta 1 (GSTT1), neuropeptide Y (NPY), and 
proteasome 26S subunit, non-ATPase 9 (PSMD9) (Itokawa et al., 
2003; Pae et al., 2004; Nordman et al., 2005; Gragnoli, 2010; Lin 
and Shuldiner, 2010; Lee et al., 2013; Tang et al., 2013; Zhang 
et al., 2013a). According to data from the Genetic Association 
Database (http://geneticassociationdb.nih.gov/) (Becker et al., 
2004), Catalog of Published Genome-Wide Association Studies 
(GWAS) (http://www.genome.gov/gwastudies/) (Hindorff 
et al., 2009), and Type 2 Diabetes Genetic Association Database 
(http://t2db.khu.ac.kr:8080/) (Lim et  al., 2010), there are 196 
schizophrenia susceptibility genes and 200 T2DM suscep-
tibility genes. Among them, 14 genes (annexin A1 [ANXA1], 
apolipoprotein E [APOE], angiotensin I  converting enzyme 
[ACE], GSTM1, interleukin 10 [IL10], methylenetetrahydrofolate 
reductase [MTHFR], NPY, paraoxonase 1 [PON1], superoxide 
dismutase 2 [SOD2], synapsin II [SYN2], tumor necrosis factor 
[TNF], uncoupling protein 2 [UCP2], serine racemase [SRR], and 
tetraspanin 18 [TSPAN18]) are common to both diseases (Liu 
et  al., 2013). These genes could be divided into 2 functional 
categories. One category is inflammation-associated genes 
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oxidative stress (GSTM1, MTHFR, PON1, SOD2, UCP2). Currently, 
the National Human Genome Research Institute–European 
Bioinformatics Institute catalog of published GWASs lists 402 
schizophrenia-susceptibility genes and 890 genes associated 
with T2DM (Nagalski et  al., 2016). They found 26 candidate 
genes that are shared by schizophrenia and T2DM. Functional 
analysis of the 79 candidate genes shared by T2DM and any of 
the severe mental illnesses (schizophrenia, bipolar disorder, 
and major depression) revealed several clusters of common 
candidate risk genes.
Other candidate genes, such as insulin like growth factor 
2 mRNA binding protein 2 (IGF2BP2) or transcription factor 
7 like 2 (TCF7L2), may also contribute to the genetic basis of 
the co-occurrence of schizophrenia and T2DM. The IGF2BP2 
polymorphisms are associated with vulnerability to schizo-
phrenia in a Han Chinese population (Zhang et  al., 2013b) 
and with impaired pancreatic β-cell function, including lower 
fasting insulin levels, which reduced glucose-stimulated 
insulin secretion (Lyssenko et  al., 2008). The TCF7L2 
polymorphisms have been detected in consistent association 
with T2DM in multiple ethnic populations, including Japanese, 
Chinese, Americans, and Asian Indians (Wang et  al., 2013). 
A  GWAS in a Greek population identified genomic regions 
with evidence of colocalizing schizophrenia and T2DM. In this 
study, the most strongly associated variant resides within 
an intron of the Parkin coregulated (PACRG) gene in schizo-
phrenia patients with T2DM vs controls, and another variant 
that reached genome-wide significance resides within the in-
tron of the TCF7L2 gene (Hackinger et al., 2018). However, the 
findings were negative in a GWAS performed in a Japanese 
population (Kajio et al., 2014).
Though common variants of SNP polymorphisms have 
only small effects, large, rare chromosomal copy number 
variants (CNVs) identified by comparative genomic ana-
lyses are known to increase the risk for schizophrenia and 
have relatively larger effects (Chen et  al., 2015; Bray and 
O’Donovan, 2018). Of more than 20,000 schizophrenia pa-
tients and controls, 8 CNVs (on chromosomes 1q21.1, 2p16.3, 
3q29, 7q11.2, 15q13.3, distal 16p11.2, proximal 16p11.2, 
and the velocardiofacial syndrome region on chromosome 
22q11.2) are associated with the onset of schizophrenia at a 
significant genome-wide threshold (CNV and Schizophrenia 
Working Groups of the Psychiatric Genomics Consortium) 
(Marshall et  al., 2017; Bray and O’Donovan, 2018). It is well 
known that 20%–30% of people with a 22q11.2 deletion have 
schizophrenia (Murphy et  al., 1999), and the prevalence of 
obesity and T2DM is reported to be greater than normal in 
22q11.2 deletion syndrome (Voll et al., 2017). A partial 22q11.2 
deletion that includes several genes related to the neuro-
psychiatric phenotype, catechol-O-methyltransferase (COMT) 
(Xiu et al., 2015) and thioredoxin reductase 2 (TXNRD2) (Kariž 
et  al., 2015), is associated with the onset of T2DM. Of 8 top 
candidate genes for schizophrenia affected by CNVs (Luo 
et  al., 2014), only B-cell CLL/lymphoma 9 (BCL9) (1q21.1), 
which is required in the Wnt signaling pathway, was reported 
to be associated with T2DM (Anderson et al., 2015) or schizo-
phrenia (Li et al., 2011), although there are not enough studies 
on the relationship between CNVs and T2DM, unlike schizo-
phrenia. Prabhanjan et  al. (2016) reported 24 CNV genes in 
patients with T2DM, and DLG associated protein 1 (DLGAP1), a 
scaffold protein of the postsynaptic density that is related to 
post-synapse neurotransmission of glutamate, is suspected 
to be genetically and functionally related to schizophrenia 
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Common Functional Cascade in Schizophrenia and 
T2DM
Rho GTPase— Disturbances in synaptic connectivity during 
perinatal and adolescent periods underlie the pathophysiology 
of schizophrenia (McGlashan and Hoffman, 2000). Postmortem 
brain studies of individuals with schizophrenia have reported 
reduced dendritic spine density in the cerebral neocortex 
(Glantz and Lewis, 2000; Konopaske et al., 2014). These dendritic 
spine abnormalities are likely the result of disturbances in the 
molecular mechanisms that contribute to spine formation, 
pruning, and/or maintenance (Glausier and Lewis, 2013). 
Dendritic spine morphogenesis is regulated through cytoskeletal 
actin, which is concentrated highly in the spines (Fischer et al., 
1998).
The Rho family of small GTPases (Rho GTPases), which in-
cludes Cdc42, Rac1, and RhoA, is a critical regulator of actin 
cytoskeleton dynamics and organization in the spines (Hall, 
1998). The activation of Rho GTPases is mediated by specific 
guanine-nucleotide exchange factors (GEFs) that catalyze the 
exchange of bound GDP (inactive state) for bound GTP (active 
state) (Van Aelst and D’Souza-Schorey, 1997). Several Rho GEFs 
that localize to dendritic spines play important roles in den-
dritic spine morphogenesis by modulating the activity of Rho 
GTPases (Xie et al., 2007).
ARHGEF11 is a specific GEF for RhoA (Rumenapp et al., 1999). 
ARHGEF11 is expressed in the pancreas, liver, adipose tissue, 
and highly in the brain (Jackson et al., 2001). ARHGEF11 variants 
are associated with a higher risk for the onset of schizophrenia 
in a Japanese population (Mizuki et al., 2014). ARHGEF11 inter-
acts and colocalizes with synapse marker postsynaptic density 
protein 95 (PSD-95) at synapse sites and negatively regulates 
the formation of dendritic spines in cortical primary neurons 
(Mizuki et al., 2016). In a yeast 2-hybrid screen, ARHGEF11 inter-
acts with disrupted-in-schizophrenia 1 (DISC1) (Millar et  al., 
2003). DISC1 directly interacts with PSD-95 and kalirin-7, a GEF 
for Rac1, and blocks access of kalirin-7 to Rac1. This binding is 
released by N-methyl-D-aspartate (NMDA) receptor activation, 
allowing free access of kalirin-7 to Rac1 and leading to the re-
sultant activation of Rac1 and spine enlargement (Hayashi-
Takagi et al., 2010). On the other hand, platelet-activating factor 
acetylhydrolase 1B1 (LIS1), one of the major binding partners of 
DISC1, is associated with RhoA activity (Kholmanskikh et  al., 
2003). Haploinsufficiency in LIS1 has also been shown to reduce 
spine density, while downregulation of RhoA rescued spine mo-
tility (Sudarov et al., 2013). DISC1 may also regulate the access 
of ARHGEF11 to RhoA, resulting in spine shrinkage. Regulation 
of Rho GTPases by DISC1 may be crucial for proper maintenance 
of the dendritic spine (Tropea et al., 2018). DISC1 (Ma et al., 2018; 
Xu et al., 2018) and kalirin (Kushima et al., 2012) are also reported 
to be associated with schizophrenia. Though DISC1 is not con-
sidered a common risk gene for schizophrenia by GWAS, DISC1 
may play critical roles as a pathological mediator in a wide 
range of psychiatric disorders (Niwa et al., 2016).
Dysfunction of insulin release from pancreatic islet β-cells 
is considered to be one of the causal factors in the etiology of 
T2DM. Rac1 is particularly important for glucose-stimulated in-
sulin secretion (Wang and Thurmond, 2009). In contrast, RhoA 
expression is increased in β-cells under diabetic conditions, 
and Rho/Rho-kinase activation is involved in the suppression 
of insulin biosynthesis (Nakamura et  al., 2006). Thus, insulin 
release from pancreatic islet β-cells could be determined by 
the resulting balance between RhoA and Rac1 activities. These 
findings suggest that Rho GTPase signaling affects not only the 
dendritic spine structure but also a number of cellular processes, 
including insulin release from pancreatic islet β-cells, and that 
aberrations in Rho GTPase signaling, including its activation by 
GEFs, could therefore contribute to the comorbidity of schizo-
phrenia and T2DM (Figure 1).
Wnt/β-Catenin
Wnts are secreted glycoproteins known as extracellular ligands. 
Wnt/β-catenin signaling (canonical pathway) is a critical and 
well-studied pathway (MacDonald et al., 2009). In the absence of 
Wnt ligands, cytoplasmic β-catenin protein is tightly regulated 
at a low level by casein kinase 1 (CK1)-mediated phosphoryl-
ation and the regulatory adenomatous polyposis coli (APC)/
axin/glycogen synthase kinase-3 (GSK-3β) complex, leading to 
its ubiquitination and subsequent proteasomal degradation 
(Gao et al., 2014). In an activated state, Wnt signaling promotes 
destruction of APC/axin/GSK-3β complex components and in-
hibition of β-catenin degradation. β-Catenin accumulates in the 
cytoplasm and eventually translocates into the nucleus, where 
it binds with T-cell factor/lymphoid enhancer factor (TCF/LEF) 
family members and induces the transcription of target genes 
(Shang et  al., 2017). The Wnt signaling pathway is crucial for 
regulating diverse biological processes such as embryonic devel-
opment, organ formation, and cell proliferation. This pathway 
plays an important role in the pathophysiology of T2DM and has 
been shown to be critical for the development of the pancreas 
and islets during embryonic growth (Papadopoulou and Edlund, 
2005). The Wnt/β-catenin pathway also plays a role in neuronal 
development (Brafman and Willert, 2017).
TCF7L2, also called TCF4, is one of the TCF/LEF family mem-
bers. The TCF7L2 gene encodes a high mobility (HMG) box that 
plays an important role in the downstream Wnt/β-catenin signal 
pathway (Hansson et al., 2010). Functionally, TCF7L2 is critical 
for β-cell proliferation and survival as well as insulin produc-
tion and secretion (Liu and Habener, 2010) and is a key regulator 
of insulin and proinsulin synthesis and processing (Zhou et al., 
2014). Although studies of TCF7L2 in brain development and 
pathologies have been relatively scarce, evidence from animal 
studies strongly implicates TCF7L2-dependent transcription in 
the development of changes in the volume of cortical areas, 
thalamo-cortical dysconnectivity, and white matter microstruc-
tural alterations (Bem et  al., 2019). TCF7L2 also regulates syn-
aptic plasticity (Kennedy et  al., 2016). Therefore, TCF7L2 may 
contribute to the comorbidity between schizophrenia and T2DM.
DISC1 also regulates the stability of Wnt/β-catenin signaling 
by an interaction with GSK3β and acts through this pathway to 
regulate neural progenitor proliferation and modulate mental 
homeostasis (Mao et  al., 2009). Disheveled-axin domain-
containing 1 (DIXDC1), a direct interacting partner of DISC1, 
contributes to psychiatric pathogenesis by regulating dendritic 
spine and glutamatergic synapse density downstream of Wnt/β-
catenin signaling (Martin et al., 2018).
Akt/GSK3
GSK3 plays several roles in differentiation and development, 
intracellular trafficking, apoptosis, and regulation of gene tran-
scription (Emamian, 2012). Some studies suggest that GSK3 in 
the brain could modulate synaptic plasticity (Emamian, 2012). 
GSK-3β is a key player of Wnt signaling pathways (Freyberg 
et  al., 2010). GSK3 is a molecule immediately downstream to 
Akt, a serine/threonine kinase (Freyberg et al., 2010). GSK3 and 
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playing a role in regulating the activity of glycogen synthesis in 
response to insulin receptor stimulation (Beaulieu, 2012). Insulin 
signals through the tyrosine kinase activity of its receptor to ac-
tivate Akt through the phosphatidylinositol 3-kinase pathway. 
Akt phosphorylates GSK-3 and inactivates it (Lovestone et  al., 
2007). Of interest, DISC1 regulates pancreatic beta-cell function, 
decreases beta-cell proliferation, and promotes apoptosis and 
glucose intolerance in transgenic mice via regulation of GSK3β 
(Jurczyk et al., 2016).
GSK3 has also been implicated in the pathogenesis of schizo-
phrenia and the actions of neurotransmission of dopamine 
(Kaidanovich-Beilin et  al., 2012). GSK3 is a major downstream 
regulator of dopamine receptor D2 (DRD2), which is targeted by 
most antipsychotics. Besides the canonical G protein-dependent 
cAMP-protein kinase A  signaling pathway, the non-canonical 
DRD2 transduction pathway is the G protein-independent Akt/
GSK3 pathway (Beaulieu et  al., 2011). Activation of DRD2 by 
dopamine facilitates the arrestin 2/protein phosphatase 2A/
Akt complex and dephosphorylates and inactivates Akt, fol-
lowed by dephosphorylation (activation) of GSK3 (Beaulieu 
et  al., 2011). Chronic administration of a dopamine agonist, 
























































Figure 1. Summary of plausible shared mechanisms for the pathogenetic association between schizophrenia and type 2 diabetes mellitus (T2DM). (A) Schematic rep-
resentation of Rho family of small GTPases (Rho GTPases) signaling cascades involved in synaptic plasticity. Rho guanine-nucleotide exchange factor 11 (ARHGEF11) 
interacts and colocalizes with synapse marker postsynaptic density protein 95 (PSD-95) at synapse sites and negatively regulated the formation of dendritic spines in 
cortical primary neurons (Mizuki et al., 2016). Disrupted-in-schizophrenia 1 (DISC1) directly interacts with PSD-95 and kalirin-7, a GEF for Rac1, and blocks access of 
kalirin-7 to Rac1. This binding is released by N-methyl-D-aspartate (NMDA) receptor activation, allowing free access of kalirin-7 to Rac1 and leading to the resultant 
activation of Rac1 and spine enlargement (Hayashi-Takagi et al., 2010). (B) The role of Rho GTPase in pancreatic β cells. Rac1 is particularly important for glucose-
stimulated insulin secretion (Wang and Thurmond, 2009). In contrast, RhoA expression is increased in β-cells under diabetic conditions, and Rho/Rho-kinase activation 
is involved in the suppression of insulin biosynthesis (Nakamura et al., 2006). Insulin release from pancreatic islet β-cells could be determined by the resulting balance 
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inhibitory phosphorylation of Akt and increased activation of 
GSK3β (Beaulieu et al., 2011). On the other hand, antipsychotics 
are able to increase Akt activation (Emamian et al., 2004; Takaki 
et al., 2018). These data establish a strong relationship between 
dopamine levels and Akt/GSK3β signaling (Singh, 2013). Akt 
and GSK-3 may be modulated by DISC1 with indirect and direct 
interactions, respectively (Dahoun et  al., 2017). The Akt/GSK-3 
pathway may be responsible for the co-occurrence of T2DM and 
schizophrenia (Lin and Shuldiner, 2010).
Multiple genetic, functional, and animal studies have shown 
that COMT is significantly associated with schizophrenia (Luo 
et  al., 2014). COMT is a prime candidate for ameliorating the 
cognitive dysfunction of schizophrenia (Tunbridge et al., 2006). 
COMT polymorphism is also associated with hyperglycemia and 
hemoglobin A1C in T2DM (Hall et al., 2016). Furthermore, COMT 
is related to the Akt/GSK3 cascade. The COMT Val108/158Met 
genotype is related to Akt phosphorylation, and information 
on functional interactions between COMT and AKt may provide 
novel insights into the pathogenesis of schizophrenia (Sei et al., 
2010).
Increasing evidence reveals regulatory interactions between 
dopamine and the central renin-angiotensin system (Oh and 
Fan, 2019). ACE catalyzes the conversion of angiotensin I to the 
active hypertensive peptide angiotensin II. Angiotensin II in-
duces dopamine release in mesolimbic dopaminergic neurons 
(Rodriguez et al., 2020). Although several studies reported that 
ACE activity is inconsistent in patients with schizophrenia, 
higher ACE activity is associated with cognitive dysfunction in 
patients with schizophrenia (Rodriguez et  al., 2020). Because 
angiotensin II increases hepatic glucose production and de-
creases insulin sensitivity, ACE inhibitor and angiotensin re-
ceptor blockers are reported to reduce the occurrence of T2DM 
(Gillespie et al., 2005).
Common Mechanisms in Schizophrenia and T2DM
Inflammation Abnormality—Inflammation is a necessary re-
sponse to infection, harmful chemicals, and tissue damage 
(Muller, 2018). Inflammation comes at the cost of a transient 
decline in tissue function, which in turn contributes to altering 
the homeostasis and becomes the pathogenesis of diseases 
(Medzhitov, 2010). The long-term effects of inflammatory medi-
ators induce neuroinflammatory disease in the brain as well as 
metabolic disease in the pancreas (Bauer and Teixeira, 2019).
The origins of inflammatory and immune activation in 
schizophrenia include (1) genetic predisposition; (2) prenatal ex-
posure to infections (Brown and Derkits, 2010), maternal inflam-
mation during pregnancy (Canetta et  al., 2014), and obstetric 
complications (Cannon et al., 2002); (3) gastrointestinal perme-
ability and the gut microbiome (Severance et al., 2016); (4) psy-
chological trauma (Popovic et al., 2019; Stilo and Murray, 2019) 
and other environmental exposures such as a low level of serum 
vitamin D (Davis et  al., 2016) and substance use (Miller et  al., 
2018); and (5) abnormalities in brain insulin action (Agarwal 
et al., 2020). These inflammations affect the development and 
activity of microglial cells, which work in the primary inflam-
mations in the central nervous system (Howes and McCutcheon, 
2017). Findings from the current meta-analysis seem to support 
elevated levels of pro-inflammatory marker cytokines, such as 
interleukin-6 (IL-6), IL-1β, and tumor necrosis factor A (TNF-A), in 
the blood and cerebrospinal fluid of patients with schizophrenia 
(Goldsmith et  al., 2016; Capuzzi et  al., 2017). Inflammatory 
markers have been found to be increased in the first episode of 
schizophrenia, and manifested alterations in the severity and 
resistance to treatment in various stages of the illness (Fineberg 
and Ellman, 2013; Upthegrove et al., 2014; Capuzzi et al., 2017). 
Furthermore, these inflammatory markers are associated with 
negative symptoms, indicating loss of brain matter and cogni-
tive impairment in patients with schizophrenia (Garcia-Rizo 
et al., 2012; Fillman et al., 2013; Meyer, 2013).
Low-grade inflammation has also been described as a risk 
factor for future development of T2DM. Many studies reported 
increased levels of pro-inflammatory markers, such as IL-6, 
IL-1β, and TNF-A, which are predictive components in patients 
with T2DM (Rehman and Akash, 2016). Pediatric studies, which 
have the advantage of not being influenced by other diseases, 
medications, or active tobacco smoking, have demonstrated 
that IL-1β, IL-6, TNF-A, and other markers are increased in in-
sulin resistance (Reinehr, 2019). Thus, pro-inflammatory me-
diators could promote insulin resistance and β-cell failure, 
ultimately resulting in the development of T2DM. Psychological 
stress can be considered to have a significant role in the onset 
and progression of diabetes (Afrisham et al., 2019). Although the 
liver and adipose tissue are important sites for the activation 
of inflammation pathways, chronic stress directly activates the 
innate immune system, which, in turn, activates the production 
of IL-6 and other cytokines (Pickup, 2004). With a genetic predis-
position, subsequent stress contributes a vulnerability factor for 
inflammation-associated schizophrenia. Multiple genome-wide 
association studies have shown that the major histocompati-
bility complex on chromosome 6p, which is known to play a key 
role in the immune system, is an important region for allelic as-
sociation in schizophrenia (Ripke, 2014). In particular, alleles of 
complement C4 within the human leukocyte antigen were found 
to be associated with schizophrenia, and C4 promotes synaptic 
elimination (Sekar et al., 2016). C4 levels also correlate with body 
mass index (Copenhaver et al., 2019). IL-1B, IL6, and IL6R genes 
were associated with schizophrenia in a meta-analysis (Hudson 
and Miller, 2018) and an association study (Kapelski et al., 2015). 
Variants in IL1B, IL6, and other cytokine genes were associated 
with T2DM in multiple studies (Achyut et al., 2007; Arora et al., 
2011; Banerjee and Saxena, 2014). An altered immune system 
and inflammatory components induced by chronic stress were 
associated with the molecular mechanisms of diabetes in 
schizophrenia (van Beveren et al., 2014; Ward and Druss, 2015).
Thus, inflammation may be a common underlying mech-
anism for schizophrenia and diabetes mellitus, which are highly 
comorbid with each other (Khandaker et al., 2017).
Oxidative Stress
Oxidative stress is defined as an imbalance between the pro-
duction of reactive oxygen species and their elimination by a 
protective mechanism (antioxidant system), which can lead to 
chronic inflammation (Hussain et al., 2016). Oxidative stress is 
harmful because excess reactive oxygen species attacks bio-
logical molecules such as proteins and DNA (Yoshikawa and 
Naito, 2002). An accumulation of oxidative damage to biological 
molecules is involved in the pathogenesis of various diseases, 
including metabolic diseases, diabetes complications, and 
neurodegenerative disorders (Emiliani et  al., 2014). Multiple 
lines of evidence have identified increased oxidative stress in 
patients with schizophrenia (Koga et  al., 2016). Most studies 
examined markers of oxidative status in the blood, such as en-
dogenous antioxidants glutathione (GSH) (Barron et  al., 2017). 
A recent extensive review found that peripheral markers of GSH 
were consistently decreased but found equivocal results for 
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Figure 2. Mechanisms that underlie the association between schizophrenia and type 2 diabetes mellitus (T2DM). The mechanisms of the increasing prevalence of 
T2DM in patients with schizophrenia are multifactorial. Poor diet and sedentary lifestyle are included in the traditional risk factors. Iatrogenic risk during treatment 
with antipsychotics is included in risk factors unique to schizophrenia (Ward and Druss, 2015). Accumulating evidence suggests shared genetic susceptibility and bio-
logical common pathway of both schizophrenia and T2DM.
(Koga et al., 2016). Genetic studies have shown associations be-
tween oxidative stress gene polymorphisms and schizophrenia, 
including genetic variations in a subunit or GSH cysteine ligase, 
the enzyme responsible for GSH synthesis, and several gluta-
thione S-transferases (GST), utilizing GSH as a co-factor (Gysin 
et  al., 2007; Gravina et  al., 2011). Meta-analysis studies have 
found the association of the most important genes of the GST 
family, GSTM1 and GSTT1 variants, with T2DM (Tang et al., 2013; 
Zhang et al., 2013a). However, unlike genetic association studies, 
the available GWASs have not provided convincing evidence 
for an oxidative stress–related genetic predisposition to schizo-
phrenia (Maas et al., 2017).
PON1 is a candidate for a gene that overlaps schizophrenia 
and T2DM. PON1 enzyme is known to have a protective effect 
against oxidative stress (Menini and Gugliucci, 2014; Bigagli and 
Lodovici, 2019). In this context, PON1 activity is inversely associ-
ated with inflammatory responses. Drug-naïve first-episode pa-
tients with schizophrenia show an inverse relationship between 
decreased activity of the enzyme PON1 and increased cytokine 
levels, including IL-6, IL-4, and IL-10 (Brinholi et al., 2015). PON1 
activity is also decreased in T2DM and related to β-cell function 
(Meneses et al., 2019).
MTHFR is a key enzyme for 1-carbon metabolism and DNA 
methylation. MTHFR polymorphisms (C677T and A1298C) are re-
lated to enzymatic activity, and an approximately 20% reduction 
of MTHFR enzyme activity is shown in patients with schizo-
phrenia (Wan et  al., 2018). Interestingly, these polymorphisms 
are frequently reported in the onset of T2DM and diabetic neph-
ropathy (Mtiraoui et al., 2007).
HPA Axis Dysfunction
The HPA axis, a neuroendocrine system, plays a fundamental 
role in the maintenance of reactions to stress and affects the 
physiologic adaptive reactions of the organism to stressors 
(Nicolaides et  al., 2015). HPA is involved in the homeostasis 
of metabolic, cardiovascular, and reproductive systems, as 
well as the immune system (van den Brink et al., 2018). The 
central stress system triggers the synthesis and secretion of 
corticotropin-releasing hormone (CRH) in the paraventricular 
nuclei of the hypothalamus (Chrousos, 1995). Through the 
hypophysial portal system, CRH reaches the anterior pitu-
itary gland and releases adrenocorticotropic hormone (ACTH) 
into the systemic circulation. On binding to the glucocorticoid 
receptors of the adrenocortical cells, ACTH subsequently in-
duces glucocorticoid synthesis and secretion, which control 
CRH and ACTH release via a negative feedback loop (van den 
Brink et al., 2018). Consequently, the blood glucocorticoid con-
centration is increased by the stress reaction. Glucocorticoids 
are steroid hormones that regulate multiple aspects of glu-
cose homeostasis. Glucocorticoids promote gluconeogenesis 
in the liver by induction of gluconeogenesis enzymes and de-
crease glucose uptake and utilization by antagonizing the in-
sulin response in skeletal muscle and adipose tissue (Chiodini 
et al., 2007). Therefore, excess or long-lasting (chronic) gluco-
corticoid exposure causes hyperglycemia and insulin resist-
ance. In patients with T2DM, glucocorticoid secretion has 
been suggested to be a possible link between insulin resist-
ance and the features of metabolic syndrome (Chiodini et al., 
2007).
Epidemiological studies have revealed that HPA activity 
plays a role in the pathophysiology of schizophrenia. Pro-
inflammatory cytokines such as IL-1, IL-6, or TNF are also 
involved in activating the HPA axis (Chrousos, 1995; Meyer, 
2013). Although there are contradictory reports (Ciufolini 
et al., 2014), schizophrenia is associated with elevated base-
line and challenge-induced HPA activity (Walker et al., 2008). 
Furthermore, control of the HPA axis was also impaired in 
drug-naïve and first-episode patients with schizophrenia 
(Ryan et  al., 2004), and baseline cortisol levels are higher in 
prodromal (clinically high risk) patients (Walker et al., 2013). 
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agreement about elevations in glucocorticoids (Bradley and 
Dinan, 2010).
Other Endocrine Systems (Prolactin)
The prolactin (PRL) pathway may contribute to the comorbidity 
of schizophrenia and T2DM (Gragnoli et  al., 2016). PRL lies on 
locus 6p22.3, which is strongly associated with T2DM in the 
GWAS replication study (Lu et  al., 2012). PRL plays a role in 
regulation of beta-cell mass (Nielsen et al., 2001), islet regener-
ation and proliferation (Nyblom et al., 2009), and insulin secre-
tion (Sorenson and Brelje, 2009). Low PRL levels are related to 
a higher T2DM risk in both sexes (Balbach et al., 2013). On the 
other hand, higher PRL levels were associated with lower glu-
cose levels and higher insulin sensitivity (Wagner et al., 2014).
PRL levels are also associated with schizophrenia. First-
episode drug-naïve male schizophrenia patients have serum 
PRL levels 3 times higher than healthy male controls (Albayrak 
et al., 2014). It has also been shown that the PRL level is nega-
tively associated with the severity of positive psychosis symp-
toms in drug-naïve male patients with schizophrenia (Ramsey 
et al., 2013). Furthermore, PRL polymorphism is associated with 
schizophrenia, especially in male patients (Rybakowski et  al., 
2012). Although increased or decreased PRL levels have not 
been found consistently across studies or by gender difference 
(Rajkumar, 2014), PRL dysfunction may sustain disrupted mental 
development and T2DM-related metabolism.
Other candidate genes, PRL-releasing hormone receptor 
(PRLRH), PRL receptor (PRLR), oxytocin (OXT), oxytocin receptor 
(OXTR), and NPY, may also correlate with the PRL pathway and 
contribute to schizophrenia and T2DM. However, genetic data on 
PRLRH, PRLR, OXT, OXTR, and NPY in human T2DM and schizo-
phrenia patients are scarce (Postolache et al., 2019).
CONCLUSION
We summarized the genetics and functional mechanisms 
underlying the comorbidity of schizophrenia and T2DM 
(Figure 2). Even when genetic analyses are performed on a rela-
tively large number of comorbid patients, the results are some-
times inconsistent, and susceptibility genes may also have only 
a low or moderate risk to the onset of both. Genetic association 
studies have revealed the number of common risk variants 
underlying diseases, but these variants explain only a propor-
tion of heritability. Among the reasons for the complexity in 
this field are suspected to be the following: (1) the heterogen-
eity of schizophrenia; (2) many environmental factors, such as 
lifestyle and vulnerability to life events, which are related to 
genetic factors; and (3) both genetic and environmental factors 
that affect common mechanisms in schizophrenia and T2DM, 
such as abnormal inflammation, oxidative stress, and HPA axis 
dysfunction. It is very difficult to distinguish purely environ-
mental factors from purely genetic factors. A new approach is 
to estimate environmental factors statistically compensated by 
digitized intermediate phenotypes directly related to genetic 
factors, such as cognitive function, structural or functional mag-
netic resonance imaging analysis, and cerebral blood flow.
On the other hand, based on many genetic and epidemio-
logical studies, the comorbidity of schizophrenia and T2DM is 
established, and it is probably safe to assume that common 
cascades and mechanisms suspected from common genes’ 
functions in the brain or pancreas are related to the onset of 
schizophrenia and T2DM. At the point of preemptive medicine, 
genetic and epidemiological information will be used in making 
decisions for the prevention and treatment of schizophrenia 
and T2DM. Though introduction of new medications or supple-
ments that are effective in these cascades and mechanisms may 
be expected, 1 target point may not be adequate because each 
common cascade and mechanism is also closely linked. In the 
future, in addition to more comprehensive whole genome and 
epigenome analyses of schizophrenia and T2DM, a more pre-
cise approach such as familial and rare gene analyses of CNVs 
of comorbid patients, further subdivision of the diagnoses of 
schizophrenia, and the following basic functional research may 
eliminate these difficulties and clarify the treatment target for 
patients with the same phenotype but different causes.
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